Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

Franco describes the importance of discussing pregnancy intentions with patients with liver disease and the need for multidisciplinary comanagement of these patients.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Mathew reviews common reasons for diagnostic delays in PBC, emphasizing the importance of timely identification and prompt treatment for improving patient outcomes.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

This clinical quiz, our third in a series of 4, focuses on recommendations for lifestyle and comorbidity management from the 2020 ACR guidelines.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Janovsky explains the importance of nutrition and dietary interventions in MASH and cirrhosis management, reviewing how providers can discuss both with patients.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

This approval expands the drug’s age range and follows recent positive phase 3 findings on dupilumab treatment for patients aged 12 to 17 with CRSwNP.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.